top of page
  • LinkedIn Logo
  • Facebook Social Icon
  • Twitter Social Icon
Search

Renal (Uraemic) Encephalopathy in Dogs and Cats

Introduction

Figure I: Kidney illustration
Figure I: Kidney illustration

Renal encephalopathy, also known as uraemic encephalopathy (UE), is a severe, life-threatening metabolic neurological disorder caused by advanced renal (kidney) failure. It occurs when the kidneys fail to filter out organic wastes, leading to an accumulation of uraemic toxins (nitrogenous toxins) in the blood and central nervous system (CNS). Besides, it also causes electrolyte imbalances, leading to metabolic acidosis, and often systemic hypertension (DiBartola, 2012; Polzin, 2011). This condition occurs in both canines and felines, particularly in severe acute kidney injury (AKI), acute-on-chronic kidney disease, and end-stage chronic kidney disease (CKD) (International Renal Interest Society [IRIS], 2023; Ross, 2023).


History

Figure II: Patient medical history taking form
Figure II: Patient medical history taking form

Typical historical features include the following:

  • Known or suspected renal disease (CKD or AKI)

  • Polyuria and polydipsia (more common in CKD)

  • Progressive anorexia, weight loss, vomiting, halitosis

  • Exposure to nephrotoxins (e.g., ethylene glycol, NSAIDs, lilies in cats)

  • Recent dehydration, shock, infection, or urinary obstruction

  • Progressive neurological decline: dullness, disorientation, tremors, seizures


In cats, a chronic history of weight loss and poor coat quality is common, whereas dogs more frequently present with gastrointestinal signs such as vomiting and diarrhoea (Ettinger et al., 2017).


Pathogenesis and Pathophysiology

The blood-brain barrier is progressively compromised during a uraemic crisis. The primary driver is the retained accumulation of hundreds of toxic metabolites, commonly termed uraemic toxins, such as urea, creatinine, guanidino compounds, and parathyroid hormone (Castro et al., 2020). The systemic effects alter central nervous tissues via multiple concurrent pathways:


Figure III: Rosner, et al. (2022)
Figure III: Rosner, et al. (2022)

Astrocyte Dysfunction:

Uraemic toxins disrupt vital organic ion transport, leading to a loss of glial fibrillary acidic protein (GFAP) in cortical grey matter (Pasumarthi et al., 2022).


Figure IV: Changes in GFAP expression during reactive astrogliosis after brain injury
Figure IV: Changes in GFAP expression during reactive astrogliosis after brain injury

White Matter Vacuolation:

Spongy degeneration and bilateral vacuolation characteristically manifest within the white matter of the basal nuclei, cerebrum, and cerebellum (Castro et al., 2020).


Figure V: Pathology of spongy degeneration and bilateral vacuolation in brain white matter
Figure V: Pathology of spongy degeneration and bilateral vacuolation in brain white matter

Cerebral Oedema:

Altered cell membrane permeability and sodium-potassium pump inhibition yield intracellular and extracellular fluid shifts (Polzin et al., 2013).


Figure VI: Cerebral Oedema – How altered cell membrane permeability and sodium-potassium pump inhibition yield intracellular and extracellular fluid shifts
Figure VI: Cerebral Oedema – How altered cell membrane permeability and sodium-potassium pump inhibition yield intracellular and extracellular fluid shifts

Secondary Hypertension:

Concurrent vascular damage can trigger arterial fibrinoid necrosis and microvascular clots, increasing stroke risks (Vaden & Langston, 2025).


Figure VII: Secondary hypertension - Vascular damage - Fibrinoid necrosis & microvascular clots – increased stroke risk
Figure VII: Secondary hypertension - Vascular damage - Fibrinoid necrosis & microvascular clots – increased stroke risk

Clinical Signs

Neurological manifestations vary in severity:

  • Depression, lethargy, altered mentation

  • Ataxia, weakness, head pressing

  • Muscle tremors or fasciculations

  • Seizures

  • Stupor or coma in severe cases

These signs result from the combined effects of uraemic toxins, metabolic acidosis, electrolyte disturbances, and possibly hypertensive encephalopathy (DiBartola, 2012).


Systemic signs include:

  • Vomiting, anorexia

  • Dehydration

  • Oral ulceration (uraemic stomatitis)

  • Halitosis (ammonia-like odour)

  • Pale mucous membranes (anaemia)

  • Oliguria or anuria in severe AKI



Canine Symptoms vs. Feline Symptoms

A spectrum of metabolic, systemic, and structural signs is usually examined by a veterinary clinician:


Clinical Feature

Canine Manifestation (Dogs)

Feline Manifestation (Cats)

Early Mental State

Moderate apathy, progressive lethargy, and mild behavioural changes (Polzin et al., 2013).

Deep depression, hiding, and profound stupor (Pasumarthi et al., 2022).

Motor Abnormalities

Fine tremors, hyperreflexia, and ataxia (Polzin et al., 2013).

Myoclonus, severe muscle twitching, and hypothermia (Castro et al., 2020).

Advanced Neurology

Generalised tonic-clonic seizures and head pressing (Ross, 2023).

Focal or grand mal seizures, progressing rapidly to a terminal coma (Pasumarthi et al., 2022).

Systemic Signs

Amaurosis (blindness) from hypertension, uraemic breath, and vomiting (Vaden & Langston, 2025)

Ulcerative stomatitis, glossitis, severe dehydration, and blindness (Castro et al., 2020).


Diagnostic Approach / Investigation

Diagnosis requires confirmation of renal dysfunction and exclusion of other metabolic or structural causes of encephalopathy. Confirming a diagnosis relies on ruling out concurrent hepatic, toxic, or structural intracranial conditions.

Recommended diagnostic approach:

  • Complete physical and neurological examination

  • Blood pressure measurement (essential to detect hypertension)

  • Complete blood count (CBC)

  • Serum biochemistry profile

  • Blood gas analysis (for acid–base status)

  • Urinalysis (including urine specific gravity and sediment)

  • Urine protein:creatinine ratio (UPC)

  • Urine culture where infection is suspected

  • Abdominal imaging (ultrasound or radiography)

  • Infectious disease testing (e.g., leptospirosis in dogs)

  • Viral testing in cats (FeLV/FIV, where indicated)

  • Fundic examination for hypertensive retinopathy


IRIS guidelines recommend staging CKD based on serum creatinine and/or SDMA, with substaging using proteinuria and systemic blood pressure (IRIS, 2023).


Figure VIII: Diagnostic approach to identify renal encephalopathy in dogs and cats. Renal encephalopathy is a diagnosis of exclusion that needs continuous reassessment and rechecking as the patient is treated.
Figure VIII: Diagnostic approach to identify renal encephalopathy in dogs and cats. Renal encephalopathy is a diagnosis of exclusion that needs continuous reassessment and rechecking as the patient is treated.

Serum Biochemistry

Reveals severe azotemia (massive elevations in blood urea nitrogen and serum creatinine) alongside severe metabolic acidosis and phosphorus imbalances (Vaden & Langston, 2025).


Cerebrospinal Fluid (CSF) Analysis

Often demonstrates elevated white blood cell counts (pleocytosis) and high protein due to altered blood-CSF barrier dynamics (Polzin et al., 2013).


Advanced Imaging (MRI/CT)

Detects diffuse bilateral cerebral oedema, structural midline shifts, or signs of ischaemic vascular strokes (Castro et al., 2020).


Histopathology (Post-Mortem)

Confirms diffuse interstitial fibrosis in the kidneys and bilateral spongy vacuolation in the brain's basal nuclei and hippocampus (Castro et al., 2020).


Interpretation of Laboratory Results


Typical laboratory findings include:

Parameter

Finding

Interpretation

Blood urea nitrogen (BUN)

Markedly increased

Reflects accumulation of uraemic toxins contributing to CNS dysfunction

Creatinine

Increased

Indicates reduced glomerular filtration rate (GFR)

SDMA

Increased

Early and sensitive indicator of decreased renal function

Phosphorus

Increased

Associated with advanced renal failure and worsened clinical signs

Potassium

Hyperkalaemia (AKI) or hypokalaemia (CKD cats)

Affects neuromuscular and cardiac function

Bicarbonate / pH

Decreased (metabolic acidosis)

Contributes to CNS depression and weakness

Calcium

Variable

Abnormalities may exacerbate neurological signs

PCV / Haematocrit

Decreased

Non-regenerative anaemia contributes to lethargy

Urine specific gravity

Isosthenuria or hyposthenuria

Indicates impaired renal concentrating ability

UPC ratio

Increased (if proteinuric)

Prognostic indicator of renal disease progression

Blood pressure

Elevated

May indicate hypertensive encephalopathy

It is important to note that neurological signs are multifactorial and not solely attributable to elevated urea levels (Polzin, 2011).


Treatment and Management

Renal encephalopathy is a medical emergency in severe cases. Treatment focuses on aggressive detoxification, neuroprotection, and balancing physiological status.


1. Fluid Resuscitation and Detoxification


Figure IX: Kidney perfusion illustration
Figure IX: Kidney perfusion illustration

Intravenous fluid therapy using balanced crystalloids should be initiated early to restore perfusion and correct dehydration, as it is crucial to optimise glomerular filtration and flush out nitrogenous toxins (Vaden & Langston, 2025). Care must be taken to prevent fluid overload, which can exacerbate cerebral oedema or pulmonary issues (Ross, 2023). Advanced veterinary referral centres utilise intermittent haemodialysis or continuous renal replacement therapy (CRRT) to clear solutes (Pasumarthi et al., 2022). Dialysis (haemodialysis or peritoneal dialysis) in severe or refractory cases should be guided by IRIS staging and tailored to individual patient parameters (IRIS, 2023; Polzin, 2011). Urine output should be monitored closely.


2. Neurological and Seizure Control


Figure X: Dog brain illustration
Figure X: Dog brain illustration

Anticonvulsants (e.g., levetiracetam or diazepam) help manage active seizure episodes (Ross, 2023). If systemic hypertension threatens central tissues or retinal structures, rapid-acting antihypertensive therapies like amlodipine must be started immediately (Vaden & Langston, 2025).


3. Acid-Base and Dietary Control


Figure XI: Renal diet
Figure XI: Renal diet

Severe metabolic acidosis requires precise bicarbonate corrections based on acid-base panels (Polzin et al., 2013). For stable animals, implementing a medical renal diet for CKD patients, restricted in highly digestible proteins, helps reduce the generation of new uraemic wastes (Vaden & Langston, 2025). Phosphate binders for persistent hyperphosphataemia and erythropoiesis-stimulating agents in chronic anaemia are also indicated. Metabolic derangements, e.g., hyperkalaemia and metabolic acidosis, need to be addressed urgently by correcting electrolyte imbalances. Symptomatically, antiemetics should be administered to control nausea and vomiting, whilst gastroprotectants are used for uraemic gastritis.


Prevention

Preventive strategies focus on early detection and slowing the progression of renal disease:


  • Routine wellness screening, especially in geriatric patients

  • Early investigation of polyuria, polydipsia, weight loss, or anorexia

  • Avoidance of nephrotoxic drugs and toxins

  • Maintenance of hydration, particularly in cats

  • Prompt treatment of urinary tract infections and obstructions

  • Early institution of renal diets in confirmed CKD

  • Monitoring of phosphorus, blood pressure, and proteinuria


Early intervention significantly improves quality of life and may delay progression to uraemic crises (Ettinger et al., 2017; IRIS, 2023).


References (APA 7th Edition)

DiBartola, S. P. (2012). Fluid, electrolyte, and acid-base disorders in small animal practice (4th ed.). Elsevier.


Castro, M. B., Klug, F. S. F., & Baccarin, R. Y. A. (2020). Uraemic encephalopathy in a Persian cat with chronic kidney disease. Journal of Comparative Pathology, 180, 24–28.


Ettinger, S. J., Feldman, E. C., & Côté, E. (2017). Textbook of Veterinary Internal Medicine (8th ed.). Elsevier.


International Renal Interest Society (IRIS). (2023). IRIS staging of CKD (modified 2023). http://www.iris-kidney.com


Management of uremic encephalopathy in a cat. Journal of Current Research in Veterinary Medicine, 4(2), 45–49. ResearchGate


National Institutes of Health. Pasumarthi, V., Ross, L., & Schweighauser, A. (2022).


Polzin, D. J. (2011). Chronic kidney disease in small animals. Veterinary Clinics of North America: Small Animal Practice, 41(1), 15–30.


Polzin, D. J., Osborne, C. A., & Ross, S. (2013). Renal-associated encephalopathy in a uremic dog. CABI Digital Library. CABI Digital Library


Rosner, M. H., Husain-Syed, F., Reis, T., Ronco, C., & Vanholder, R. (2022). Uremic encephalopathy. Kidney International, 101(2), 227–241. https://doi.org/10.1016/j.kint.2021.09.025


Ross, L. (2023). Acute kidney injury in dogs and cats. MSD Veterinary Manual. MSD Veterinary Manual


Vaden, S. L., & Langston, C. E. (2025). How I treat uremic crises in dogs and cats with chronic kidney disease. Veterinary Information Network (VIN). Veterinary Information Network



 
 
 

Comments

bottom of page